CJC-1295 No DAC – 5mg 
A Modified GHRH (1-29) Analog for Growth Hormone Axis Research
A Short-Acting GHRH Analog (Mod GRF 1-29) for Somatotropic Signaling Studies

Category: Peptide Research Compounds / Endocrinology / Growth Hormone Axis Biology

For Research Use Only. Not for human or veterinary use. Not a drug, supplement, or food additive. Intended exclusively for in-vitro and laboratory research by qualified investigators.

DISCLAIMER
ATTENTION: PRIMALRESEARCHLABS.COM products are intended for laboratory research and in-vitro studies only. All information presented is for educational and research purposes related to scientific investigation. These products are strictly not for human or veterinary use, consumption, or diagnostic applications. They are not pharmaceuticals, food additives, or dietary supplements. By purchasing from PRIMALRESEARCHLABS.COM, you acknowledge that you are a qualified researcher operating in a controlled laboratory environment. Adhere to all applicable local, state, and federal laws and regulations regarding handling and use of research chemicals. Use appropriate personal protective equipment (PPE) and follow laboratory safety protocols.

BIOLOGY
CJC-1295 without DAC, also known as Modified GRF (1-29), is a synthetic analog of the first 29 amino acids of growth-hormone-releasing hormone (GHRH) — the shortest fully functional fragment of native GHRH. It contains amino-acid substitutions that improve resistance to enzymatic degradation while retaining activity at the GHRH receptor. Unlike the DAC (Drug Affinity Complex) version, the no-DAC form does not covalently bind albumin and therefore has a shorter duration of action.

CJC-1295 acts on pituitary somatotrophs via the GHRH receptor, triggering cAMP signaling that promotes growth-hormone synthesis and release. It has been studied in preclinical and clinical research models examining the somatotropic axis, pulsatile GH secretion, and downstream IGF-1 production, making it a valuable tool for in-vitro and in-vivo endocrinology research.

This product is intended solely for in-vitro and preclinical research use and is not for human or veterinary consumption.

KEY RESEARCH APPLICATIONS OF CJC-1295 NO DAC

1. GHRH Receptor Signaling
CJC-1295 No DAC demonstrates significant activity in endocrinology studies through:
• GHRH Receptor Activation: Binds and activates pituitary GHRH receptors.
• cAMP Signaling: Triggers intracellular cAMP cascades driving GH transcription.
• GH Synthesis & Release: Stimulates growth-hormone production and secretion.
Supporting Studies:
Teichman, S.L. et al. — Journal of Clinical Endocrinology & Metabolism. “Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone.” PubMed – PMID: 16352683

2. Pulsatile GH Secretion & IGF-1 Axis
Investigated in somatotropic-axis research models through:
• Pulsatility: Studied for preservation of pulsatile GH secretion patterns.
• IGF-1 Downstream: GH stimulation studied for downstream IGF-1 elevation.
• Trough GH Levels: Examined for effects on inter-pulse GH concentrations.
Supporting Studies:
Ionescu, M. & Frohman, L.A. — Journal of Clinical Endocrinology & Metabolism. “Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295.” PubMed – PMID: 17018654

3. GHRH Analog Pharmacology
Explored in broader endocrinology research through:
• Receptor Pharmacology: Reference GHRH analog for receptor characterization.
• Bioconjugate Comparison: Studied alongside DAC-modified long-acting analogs.
• Translational Endocrinology: Applied across pituitary and GH-axis research.
Supporting Studies:
Jetté, L. et al. — Endocrinology. “hGRF(1-29)-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.” PubMed – PMID: 15817669

RECOMMENDED RESEARCH CONCENTRATIONS
For laboratory research reference only. Not for human or veterinary use.
• In-vitro pituitary cell assays — 1-100 nM — Assay buffer
• Receptor signaling studies — 1-50 nM — Cell culture media
• Animal models (rodents, SC) — Per protocol — Injection

WHY CHOOSE PRIMAL RESEARCH FOR YOUR CJC-1295 NO DAC STUDIES?
• ≥98% HPLC-verified purity — critical for GHRH receptor studies
• Independent third-party batch testing with COA available on request
• Lyophilized powder for maximum stability and long-term storage
• Available in 5mg and 10mg quantities — supports scalable endocrinology protocols

STORAGE & HANDLING
• Store at -20°C, desiccated and protected from light
• Soluble in sterile water or bacteriostatic water
• Prepare fresh solutions prior to each experiment
• Avoid repeated freeze-thaw cycles

TECHNICAL SPECIFICATIONS
Compound: CJC-1295 No DAC (Modified GRF 1-29)
Molecular Weight: ~3368 g/mol
Purity: ≥98% (HPLC Verified)
Form: Lyophilized powder — 5mg and 10mg
Storage: -20°C, desiccated, light-protected
Solubility: Soluble in sterile or bacteriostatic water
COA: Available per batch on request

ADVANCE YOUR RESEARCH
Order your CJC-1295 No DAC today to support advanced research in GHRH receptor signaling, pulsatile growth-hormone secretion, and somatotropic axis biology.

Primal Research products are sold strictly for in-vitro and laboratory research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease or condition. Purchasers are responsible for compliance with all applicable local, state, and federal regulations.